HealthTree Logo
search more_vert
close
person Sign In / Create Account
The very exciting ALT-803 myeloma immunotherapy with Dr. Sarah Holstein, MD, PhD at Roswell Park
The very exciting ALT-803 myeloma immunotherapy with Dr. Sarah Holstein, MD, PhD at Roswell Park image
HealthTree Podcast for Multiple Myeloma
event Sep 19, 2014 / 11:00AM MDT

Event Description

 

Tell your musician friends to donate a song today on Songs For Life to help raise funds for multiple myeloma research! Dr. Sarah Holstein, MD, PhD, Roswell Park Cancer Institute Interview Date: September 19, 2014

 Dr. Sarah Holstein describes a very exciting new immunotherapy that will open in a Phase I/II clinical trial shortly. This new drug called ALT-803 by Altor Bioscience was listed as one of the most exciting immunotherapy choices according to the NCI. In experiments in mice, it changed the immune system to kill myeloma cells and then trained the immune system with a memory to continue attacking it, even when more myeloma cells were injected. Dr. Holstein shares the details of how this new therapy works. She also discusses her research to "choke" myeloma cells with their own product by leveraging the secretory nature of myeloma (the production of the M-spike). Additionally, she shares three strategies to overcome bortezomib resistance - 1) using HDAC inhibitors, 2)Using new heat shock proteins and 3) Manipulating the bone marrow microenvironment. There is much to learn in this excellent show. The live mPatient Myeloma Radio podcast with Dr. Sarah Holstein, MD, PhD,

Schedule & Agenda

person
The very exciting ALT-803 myeloma immunotherapy with Dr. Sarah Holstein, MD, PhD at Roswell Park
11:00AM
Dr. Sarah Holstein & Jennifer Ahlstrom

Speakers & Moderators

The panelist Sarah Holstein, MD, PhD
Sarah Holstein, MD, PhD

Dr. Holstein is a physician-scientist who specializes in the treatment of multiple myeloma and related plasma cell dyscrasias. Prior to joining the faculty at UNMC, Dr. Holstein served as a myeloma specialist at the Roswell Park Cancer Institute and the University of Iowa. Her laboratory is focused on gaining a better understanding of the pathophysiology of multiple myeloma and the development of novel therapeutic agents for multiple myeloma. Her laboratory research has received funding from such sources as the National Institutes of Health, the American Society of Hematology, and the PhRMA Foundation. Dr. Holstein is an active clinical investigator, and has been involved in clinical trials for patients with newly diagnosed myeloma, with relapsed/refractory disease, as well as in the post-transplant maintenance setting. She has written numerous peer-reviewed research articles as well as review articles and book chapters. She is a member of the Alliance Multiple Myeloma Committee and the NCCN Multiple Myeloma Panel.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Regeneron
Adaptive
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube